Presentation is loading. Please wait.

Presentation is loading. Please wait.

Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H

Similar presentations


Presentation on theme: "Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H"— Presentation transcript:

1 Improved Survival of Stage I Non–Small Cell Lung Cancer: A VA Central Cancer Registry Analysis 
Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H. Harpole, MD, Mark W. Onaitis, MD, Michael J. Kelley, MD, Joseph K. Salama, MD  Journal of Thoracic Oncology  Volume 12, Issue 12, Pages (December 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Improvement in survival of the radiation cohort with stereotactic body radiation therapy (SBRT) versus with conventionally fractionated radiation (CRT). (A) Four-year OS by year of diagnosis for patients treated with surgery, radiation, or no treatment. Data are mean plus or minus SE. (B) Proportion of patients treated with radiation who underwent CRT and SBRT, by year of diagnosis. (C) Overall survival of all patients undergoing either CRT or SBRT. (D) Lung cancer–specific survival of all patients undergoing either CRT or SBRT. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Trends in utilization of surgical modalities and associated survival. (A) Proportion of surgical patients undergoing each procedure by the year of diagnosis. (B) Overall survival of surgical patients by modality. (C) Lung cancer–specific survival of surgical patients by modality. (D) Overall status of propensity score–matched surgical patients undergoing video-assisted thoracoscopic surgical (VATS) or open lobectomy. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Survival after lobectomy is improved over that after sublobar resection for medically fit patients. (A) Overall survival (OS) of propensity score–matched surgical patients undergoing lobectomy or sublobar resection by either a video-assisted thoracoscopic surgical (VATS) or open procedure. (B) Four-year OS after lobectomy or sublobar resection, either VATS or open, for patients with a CCI of 0 or 1. Data are mean plus or minus SE. (C) Four-year OS after lobectomy or sublobar resection, either VATS or open, for patients with a CCI of 2. Data are mean plus or minus SE. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

5 Figure 4 Survival after lobectomy is superior to stereotactic body radiation therapy (SBRT). (A) Overall survival of all patients undergoing surgery, radiation, or no treatment. (B) Lung cancer–specific survival of all patients undergoing surgery, radiation, or no treatment. (C) Overall survival of propensity score–matched patients treated by either lobectomy or SBRT. (D) Lung cancer–specific survival of propensity score–matched patients treated by either lobectomy or SBRT. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

6 Supplementary Tables 1 and 2
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

7 Supplementary Figure 1 Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

8 Supplementary Figure 2A
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

9 Supplementary Figure 2B
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

10 Supplementary Figure 3A
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

11 Supplementary Figure 3B
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

12 Supplementary Figure 3C
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

13 Supplementary Figure 3D
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

14 Supplementary Figure 4 Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

15 Supplementary Table 3 Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

16 Supplementary Table 4 Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

17 Supplementary Table 5 Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

18 Supplementary Table 6 Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

19 Supplementary Figure 5A
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

20 Supplementary Figure 5B
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

21 Supplementary Figure 5C
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

22 Supplementary Figure 5D
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

23 Supplementary Figure 5E
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

24 Supplementary Table 7 Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

25 Supplementary Figure 6A
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

26 Supplementary Figure 7A
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

27 Supplementary Figure 7B
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

28 Supplementary Table 8 Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

29 Supplementary Figure 8A
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

30 Supplementary Figure 8B
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

31 Supplementary Table 9 Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions


Download ppt "Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H"

Similar presentations


Ads by Google